Earnings ·
Dyadic International reported second-quarter 2026 financial results for the period ended June 30, 2026
DYAIDyadic International Inc
Dyadic International reported second-quarter 2026 financial results for the period ended June 30, 2026. Total revenue was $961,138, a decrease of 0.6% from the prior year period, driven by lower research and development revenue partially offset by increased grant revenue. The company reported a net loss of $2,123,884, or $(0.06) per share, compared to a net loss of $1,793,774 in the same period last year. Loss from operations widened to $2,054,204 due to higher costs of revenue and general and administrative expenses, despite lower research and development spending. Cash and equivalents stood at $1,425,364 as of June 30, 2026. Dyadic International is a global biotechnology company that produces precision-engineered, animal-free proteins and enzymes using proprietary microbial platforms.